Related references
Note: Only part of the references are listed.Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Daniele Piovani et al.
JOURNAL OF CROHNS & COLITIS (2021)
775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
Bruce E. Sands et al.
GASTROENTEROLOGY (2021)
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment
Michel Adamina et al.
JOURNAL OF CROHNS & COLITIS (2020)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
Kenji Watanabe et al.
JOURNAL OF GASTROENTEROLOGY (2020)
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial
Baili Chen et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]
Tadakazu Hisamatsu et al.
JOURNAL OF CROHNS & COLITIS (2019)
Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses
Daniele Piovani et al.
GASTROENTEROLOGY (2019)
Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
Tadakazu Hisamatsu et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease
Julian Panes et al.
GASTROENTEROLOGY (2018)
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2
Brian G. Feagan et al.
JOURNAL OF CROHNS & COLITIS (2018)
Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan
Kouhei Fukushima et al.
SURGERY TODAY (2018)
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease
Paul Rutgeerts et al.
GASTROENTEROLOGY (2018)
FISTULA HEALING IN PIVOTAL STUDIES OF USTEKINUMAB IN CROHN'S DISEASE
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2016)
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial
Takayuki Matsumoto et al.
JOURNAL OF CROHNS & COLITIS (2016)
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial
Julian Panes et al.
LANCET (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study
A. Tursi et al.
TECHNIQUES IN COLOPROCTOLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts et al.
GASTROENTEROLOGY (2012)
Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial
Koji Yoshida et al.
INFLAMMATORY BOWEL DISEASES (2012)
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
Mamoru Watanabe et al.
JOURNAL OF CROHNS & COLITIS (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Postoperative Infliximab Is Not Associated with An Increase in Adverse Events in Crohn's Disease
Miguel Regueiro et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2009)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study
Oliver Schroeder et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2006)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
MJ Sweeting et al.
STATISTICS IN MEDICINE (2004)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
